Transcription factor Sp1 induces ADAM17 and contributes to tumor cell invasiveness under hypoxia

被引:55
作者
Szalad, Alexandra [2 ]
Katakowski, Mark [1 ]
Zheng, Xuguang [1 ]
Jiang, Feng [1 ]
Chopp, Michael [1 ,2 ]
机构
[1] Henry Ford Hosp, Dept Neurol, Detroit, MI 48202 USA
[2] Oakland Univ, Dept Phys, Rochester, MI 48309 USA
关键词
HUMAN GASTRIC-CANCER; EXPRESSION; INHIBITION; TISSUE; INVOLVEMENT; ACTIVATION; INVASION; THERAPY; GLIOMA; ALPHA;
D O I
10.1186/1756-9966-28-129
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: Expression of the Sp1 transcription factor is induced by hypoxia, and the ADAM17 promoter contains predicted Sp1 binding sites. ADAM17 contributes to hypoxic-induce invasiveness of glioma. In this study, we investigated whether Sp1 transcription factor induces ADAM17 and/or contributes to tumor cell invasiveness in hypoxia. Methods: Employing RT-PCR and Western blot, we examined the role of Sp1 in ADAM17 transcription/expression under normoxic and hypoxic conditions, and whether it binds to the ADAM17 GC-rich promoter region using a chromatin immunoprecipitation assay. Additionally, we tested the effect of Sp1 suppression in tumor cell invasion and migration, using Matrigel basement membrane invasion chambers, a scratch wound-healing assay, and small interfering RNA. Results: Here, we found that Sp1 binds to the ADAM17 promoter, and that Sp1 regulates ADAM17 expression under hypoxia. Furthermore, suppression of Sp1 decreases invasiveness and migration in U87 tumor cells. Conclusion: Our findings suggest the Sp1 transcription factor mediates ADAM17 expression under hypoxia, regulates glioma invasiveness, and thus, may be a target for anti-invasion therapies.
引用
收藏
页数:9
相关论文
共 26 条
[1]   Hypoxia Helps Glioma to Fight Therapy [J].
Amberger-Murphy, Verena .
CURRENT CANCER DRUG TARGETS, 2009, 9 (03) :381-390
[2]   ADAM17 as a Therapeutic Target in Multiple Diseases [J].
Arribas, Joaquin ;
Esselens, Cary .
CURRENT PHARMACEUTICAL DESIGN, 2009, 15 (20) :2319-2335
[3]   Putative function of ADAM9, ADAM10, and ADAM17 as APP α-secretase [J].
Asai, M ;
Hattori, C ;
Szabó, B ;
Sasagawa, N ;
Maruyama, K ;
Tanuma, S ;
Ishiura, S .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2003, 301 (01) :231-235
[4]   Adams: Key components in EGFR signalling and development [J].
Blobel, CP .
NATURE REVIEWS MOLECULAR CELL BIOLOGY, 2005, 6 (01) :32-43
[5]   TACE is required for the activation of the EGFR by TGF-α in tumors [J].
Borrell-Pagès, M ;
Rojo, F ;
Albanell, J ;
Baselga, J ;
Arribas, J .
EMBO JOURNAL, 2003, 22 (05) :1114-1124
[6]   Oxygen-mediated regulation of gelatinase and tissue inhibitor of metalloproteinases-1 expression by invasive cells [J].
Canning, MT ;
Postovit, LM ;
Clarke, SH ;
Graham, CH .
EXPERIMENTAL CELL RESEARCH, 2001, 267 (01) :88-94
[7]   Central role of Sp1-regulated CD39 in hypoxia/ischemia protection [J].
Eltzschig, Holger K. ;
Koehler, David ;
Eckle, Tobias ;
Kong, Tianqing ;
Robson, Simon C. ;
Colgan, Sean P. .
BLOOD, 2009, 113 (01) :224-232
[8]  
FRIEDL HP, 1971, REV EUR ETUD CL BIOL, V16, P268
[9]   Tumour-cell invasion and migration: Diversity and escape mechanisms [J].
Friedl, P ;
Wolf, K .
NATURE REVIEWS CANCER, 2003, 3 (05) :362-374
[10]  
GLUNDE K, 2009, CANCER BIOL THER, V8, P1151